scispace - formally typeset
Journal ArticleDOI

Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation.

Reads0
Chats0
TLDR
Overall, several flavonoids from P. corylifolia might be useful remedies for treating inflammatory diseases by inhibiting IL-6-induced STAT3 activation and phosphorylation.
Abstract
Inhibiting interleukin-6 (IL-6) has been postulated as an effective therapy in the pathogenesis of several inflammatory diseases. In this study, seven flavonoids were isolated from the methanol extracts of Psoralea corylifolia by bioactivity-guided fractionation. The structures of bakuchiol (1), bavachinin (2), neobavaisoflavone (3), corylifol A (4), corylin (5), isobavachalcon (6), and bavachin (7) were determined by spectroscopic analysis (1H-, 13C- NMR and MS). We demonstrated that compounds 1-7 showed an inhibitory effect on IL-6-induced STAT3 promoter activity in Hep3B cells with IC50 values of 4.57 ± 0.45, 3.02 ± 0.53, 2.77 ± 0.02, 0.81 ± 0.15, 1.37 ± 0.45, 2.45 ± 0.13, and 4.89 ± 0.05 µΜ, respectively. These compounds also inhibited STAT3 phosphorylation induced by IL-6 in Hep3B cells. Overall, several flavonoids from P. corylifolia might be useful remedies for treating inflammatory diseases by inhibiting IL-6-induced STAT3 activation and phosphorylation.

read more

Citations
More filters
Journal ArticleDOI

The Chemical Constituents and Bioactivities of Psoralea corylifolia Linn.: A Review.

TL;DR: This paper systematically summarized literatures on the chemical constituents and biological activities of P. corylifolia, which provided useful information for the further research and development toward this potent medicinal plant.
Journal ArticleDOI

Sesquiterpene dimer (DSF-52) from Artemisia argyi inhibits microglia-mediated neuroinflammation via suppression of NF-κB, JNK/p38 MAPKs and Jak2/Stat3 signaling pathways

TL;DR: The inhibitory ability of DSF-52 on microglia- mediated neuroinflammation may offer a novel neuroprotective modality and could be potentially useful in inflammation-mediated neurodegenerative diseases.
Journal ArticleDOI

Bavachin attenuates LPS-induced inflammatory response and inhibits the activation of NLRP3 inflammasome in macrophages

TL;DR: The experimental results indicated anti-inflammatory effects of bavachin exhibit attenuation of LPS-induced inflammation and inhibit activation of NLRP3 inflammasome in macrophages, suggesting that bavchin might have potential in treating inflammatory and autoimmune diseases.
Journal ArticleDOI

Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia

TL;DR: The experimental results demonstrated that corylin suppressed the production of NO and proinflammatory cytokines by LPS-activated BV2 cells, suggesting that c Corylin might have potential in treating brain inflammation and attenuating the progression of neurodegeneration diseases.
References
More filters
Journal ArticleDOI

Inflammatory Cytokines Impair Endothelium-Dependent Dilatation in Human Veins In Vivo

TL;DR: The results demonstrate that pro-inflammatory cytokines induce transient and reversible endothelial dysfunction and indicate that cyclooxygenase activity may contribute to the genesis of the effect.
Journal ArticleDOI

Tissue factor transcription driven by egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia

TL;DR: A novel biology for hypoxia-induced fibrin deposition is delineated, in which oxygen deprivation-induced activation of Egr-1, resulting in expression of tissue factor, has an unexpected and central role.
Journal ArticleDOI

IL-6 is required for airway mucus production induced by inhaled fungal allergens.

TL;DR: IL-6 is a key regulator of specific hallmark features of allergic airway inflammation and it could be a potential target for pulmonary diseases that are associated with goblet cell metaplasia and mucus hypersecretion.
Journal ArticleDOI

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.

TL;DR: In vitro and in vivo anti-multiple myeloma activity of monoclonal antibody 1339, a high-affinity fully humanized anti-interleukin 6 mAb (immunoglobulin G1), alone and in combination with conventional and novel anti- Multiple Myeloma agents, as well as its effect on bone turnover are confirmed.
Related Papers (5)